Mouth-opening Device As a Treatment Modality in Trismus Patients with Head and Neck Cancer and Oral Submucous Fibrosis: a Prospective Study
Overview
Affiliations
Objectives: This study investigated the clinical effectiveness of intervention with an open-mouth exercise device designed to facilitate maximal interincisal opening (MIO) and improve quality of life in patients with head and neck (H&N) cancer and oral submucous fibrosis (OSF).
Materials And Methods: Sixty patients with H&N cancer, OSF, and trismus (MIO < 35 mm) participated in the functional rehabilitation program. An open-mouth exercise device intervention group and conventional group, each consisting of 20 patients, underwent a 12-week training and exercising program and follow-up. For the control group, an additional 20 patients were randomly selected to match the demographic characteristics of the aforementioned two groups.
Results: The patients' MIO improvements in the aforementioned three groups were 14.0, 10.5, and 1.3 mm, respectively.
Conclusion: Results of this study confirm the significant improvement in average mouth-opening range. In addition, according to patient feedback, significant improvements in health-related quality of life and reductions in trismus symptoms occurred in the open-mouth exercise device group.
Clinical Relevance: This newly designed open-mouth exercise device can facilitate trismus patients with H&N cancer and OSF and improve mouth-opening range and quality of life.
Wu H, Wang Z, Han J, Wu T, Zhai G, Zhang C Sensors (Basel). 2024; 24(6).
PMID: 38544251 PMC: 10975241. DOI: 10.3390/s24061988.
Interventions for managing oral submucous fibrosis.
Jones A, Veale B, Li T, Aggarwal V, Twigg J Cochrane Database Syst Rev. 2024; 2:CD007156.
PMID: 38415846 PMC: 10900301. DOI: 10.1002/14651858.CD007156.pub3.
Nedeljak J, Armijo-Olivo S, Hernandez I, Nayar S, McNeel M Physiother Can. 2023; 74(2):173-183.
PMID: 37323716 PMC: 10262739. DOI: 10.3138/ptc-2020-0068.
Effect of Oral Exercise on Trismus after Oral Cancer Radiotherapy: A Quasi-Experimental Study.
Wang T, Wu K, Wang H, Liang S, Lin T, Chen Y Biomedicines. 2022; 10(11).
PMID: 36428519 PMC: 9687315. DOI: 10.3390/biomedicines10112951.
Parke S, Langelier D, Cheng J, Kline-Quiroz C, Stubblefield M Curr Oncol Rep. 2022; 24(4):517-532.
PMID: 35182293 DOI: 10.1007/s11912-022-01227-x.